Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand
Journal of Thrombosis and Haemostasis · 2024-01 · 22 (1) · 271-285
DOI: 10.1016/j.jtha.2023.09.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-01. Verfasst von Eleyna M Martin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK. Electronic address: e.martin.2@bham.ac.uk. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Single-Domain Antibodies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Horizon 2020, NIHR Imperial Biomedical Research Centre.
Abstract (Originalsprache)
BACKGROUND: Clustering of the receptors glycoprotein receptor VI (GPVI), C-type lectin-like receptor 2 (CLEC-2), low-affinity immunoglobulin γ Fc region receptor II-a (FcγRIIA), and platelet endothelial aggregation receptor 1 (PEAR1) leads to powerful activation of platelets through phosphorylation of tyrosine in their cytosolic tails and initiation of downstream signaling cascades. GPVI, CLEC-2, and FcγRIIA signal through YxxL motifs that activate Syk. PEAR1 signals through a YxxM motif that activates phosphoinositide 3-kinase. Current ligands for these receptors have an undefined valency and show significant batch variation and, for some, uncertain specificity. OBJECTIVES: We have raised nanobodies against each of these receptors and multimerized them to identify the minimum number of epitopes to achieve robust activation of human platelets. METHODS: Divalent and trivalent nanobodies were generated using a flexible glycine-serine linker. Tetravalent nanobodies utilize a mouse Fc domain (IgG2a, which does not bind to FcγRIIA) to dimerize the divalent nanobody. Ligand affinity measurements were determined by surface plasmon resonance. Platelet aggregation, adenosine triphosphate secretion, and protein phosphorylation were analyzed using standardized methods. RESULTS: Multimerization of the nanobodies led to a stepwise increase in affinity with divalent and higher-order nanobody oligomers having sub-nanomolar affinity. The trivalent nanobodies to GPVI, CLEC-2, and PEAR1 stimulated powerful and robust platelet aggregation, secretion, and protein phosphorylation at low nanomolar concentrations. A tetravalent nanobody was required to activate FcγRIIA with the concentration-response relationship showing a greater variability and reduced sensitivity compared with the other nanobody-based ligands, despite a sub-nanomolar binding affinity. CONCLUSION: The multivalent nanobodies represent a series of standardized, potent agonists for platelet glycoprotein receptors. They have applications as research tools and in clinical assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK. Electronic address: e.martin.2@bham.ac.uk.
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK; Centre of Membrane Proteins and Receptors (COMPARE), The Universities of Birmingham and Nottingham, The Midlands, UK.
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
- Institute for Transfusion Medicine-Skopje, Skopje, North Macedonia.
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK; Current address: School of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, UK.
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK; Centre of Membrane Proteins and Receptors (COMPARE), The Universities of Birmingham and Nottingham, The Midlands, UK. Electronic…
Förderung
- Wellcome Trust
- Horizon 2020
- NIHR Imperial Biomedical Research Centre
- Horizon 2020 Framework Programme
- Birmingham Biomedical Research Centre
- H2020 Marie Skłodowska-Curie Actions
- British Heart Foundation
- National Institute for Health and Care Research
Zitieren
APA
Martin, E. M., Clark, J. C., Montague, S. J., Morán, L. A., Di, Y., Bull, L. J., Whittle, L., Raka, F., Buka, R. J., Zafar, I., Kardeby, C., Slater, A., & Watson, S. P. (2024). Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand. Journal of Thrombosis and Haemostasis, 22(1), 271-285. https://doi.org/10.1016/j.jtha.2023.09.026
Vancouver
Martin EM, Clark JC, Montague SJ, Morán LA, Di Y, Bull LJ, et al. Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand. Journal of Thrombosis and Haemostasis. 2024;22(1):271-285. doi:10.1016/j.jtha.2023.09.026
BibTeX
@article{Martin2024,
author = {Martin, Eleyna M and Clark, Joanne C and Montague, Samantha J and Morán, Luis A and Di, Ying and Bull, Lily J and Whittle, Luke and Raka, Florije and Buka, Richard J and Zafar, Idrees and Kardeby, Caroline and Slater, Alexandre and Watson, Steve P},
title = {Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
volume = {22},
number = {1},
pages = {271--285},
doi = {10.1016/j.jtha.2023.09.026}
}
EUVIMED